{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T13:45:32Z","timestamp":1772718332067,"version":"3.50.1"},"reference-count":58,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003122","name":"Ferring Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003122","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/13696998.2026.2630599","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T12:40:34Z","timestamp":1772714434000},"page":"672-687","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Budget impact model of nadofaragene firadenovec for the treatment of high-risk non-muscle-invasive bladder cancer that is unresponsive to Bacillus Calmette-Gu\u00e9rin immunotherapy"],"prefix":"10.1080","volume":"29","author":[{"given":"Min","family":"Yang","sequence":"first","affiliation":[{"name":"Analysis Group, Inc.","place":["Boston, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinglei","family":"Chai","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc.","place":["Boston, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongni","family":"Ye","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc.","place":["Boston, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Zhao","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc.","place":["Boston, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashton","family":"Moradi","sequence":"additional","affiliation":[{"name":"Ferring Pharmaceuticals","place":["Parsippany, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yair","family":"Lotan","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas Southwestern Medical Center","place":["Dallas, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"e_1_3_9_2_1","unstructured":"National Cancer Institute. Surveillance Epidemiology and End Results (SEER) program. Cancer Stat Facts: Bladder Cancer; 2023. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html. [accessed 2023 April 7]."},{"key":"e_1_3_9_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/medsci8010015"},{"key":"e_1_3_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.06.049"},{"key":"e_1_3_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.05.041"},{"key":"e_1_3_9_6_1","doi-asserted-by":"publisher","DOI":"10.4111\/icu.20210278"},{"key":"e_1_3_9_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756287215599694"},{"key":"e_1_3_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67707-5"},{"key":"e_1_3_9_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.6901"},{"key":"e_1_3_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.10.039"},{"key":"e_1_3_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.05.045"},{"key":"e_1_3_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30512-8"},{"key":"e_1_3_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.07.031"},{"key":"e_1_3_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2016.05.027"},{"key":"e_1_3_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.06.020"},{"key":"e_1_3_9_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.4_suppl.701"},{"key":"e_1_3_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67799-3"},{"key":"e_1_3_9_18_1","unstructured":"United States Food and Drug Administration. Highlights of prescribing information: VALSTAR (valrubicin); 2025. Available from: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020892s013lbl.pdf. [accessed 2025 October 29]."},{"key":"e_1_3_9_19_1","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Bladder Cancer V.2.2025. \u00a9 National Comprehensive Cancer Network Inc; 2025. All rights reserved. To view the most recent and complete version of the guideline go online to NCCN.org. [accessed 2025 December 10]."},{"key":"e_1_3_9_20_1","unstructured":"Merck Sharp & Dohme Corp. KEYTRUDA\u00ae (pembrolizumab) Prescribing Information; 2025. Available from: https:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf. [accessed 2025 October 29]."},{"key":"e_1_3_9_21_1","unstructured":"United States Food and Drug Administration. FDA approves first adenoviral vector-based gene therapy for high-risk Bacillus Calmette-Gu\u00e9rin unresponsive non-muscle invasive bladder cancer; 2025. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-first-adenoviral-vector-based-gene-therapy-high-risk-bacillus-calmette-guerin. [accessed 2025 October 29]."},{"key":"e_1_3_9_22_1","unstructured":"United States Food and Drug Administration. FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer; 2025. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nogapendekin-alfa-inbakicept-pmln-bcg-unresponsive-non-muscle-invasive-bladder-cancer. [accessed 2025 October 29]."},{"key":"e_1_3_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30540-4"},{"key":"e_1_3_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.08.2291"},{"key":"e_1_3_9_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.JU.0001009548.76580.ba.11"},{"key":"e_1_3_9_26_1","unstructured":"National Cancer Institute. Surveillance Epidemiology and End Results (SEER) Program. Cancer Query System: Cancer Prevalence Database; 2024. Available from: https:\/\/surveillance.cancer.gov\/prevalence\/canques.html. [accessed 2024 April 29]."},{"key":"e_1_3_9_27_1","volume-title":"88th Annual Meeting, New England Section of the American Urological Association","author":"Song J","year":"2019","unstructured":"Song J, Georgieva MV, Bocharova I, et al. Contemporary data on incidence, treatments and outcomes of Tis, high-grade Ta, and high-grade T1 non-muscle invasive bladder cancer patients in the US. 88th Annual Meeting, New England Section of the American Urological Association; September 12\u201314; Providence, RI; 2019."},{"key":"e_1_3_9_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.3064"},{"key":"e_1_3_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.04.1547"},{"key":"e_1_3_9_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000162059.64886.1c"},{"key":"e_1_3_9_31_1","unstructured":"United States Food and Drug Administration. Highlights of prescribing information: VALSTAR\u00ae (valrubicin). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/020892s019lbl.pdf. [accessed 2025 June 1]."},{"key":"e_1_3_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2012.04.010"},{"key":"e_1_3_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.09.005"},{"key":"e_1_3_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.04.031"},{"key":"e_1_3_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00147-9"},{"key":"e_1_3_9_36_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/656918"},{"key":"e_1_3_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2011.04.073"},{"key":"e_1_3_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2022.10.030"},{"key":"e_1_3_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2023.06.018"},{"key":"e_1_3_9_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.716"},{"key":"e_1_3_9_41_1","doi-asserted-by":"publisher","DOI":"10.3109\/02656736.2014.882021"},{"key":"e_1_3_9_42_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756287214541798"},{"key":"e_1_3_9_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000136446.37840.0a"},{"key":"e_1_3_9_44_1","unstructured":"Truven Redbook Online. Wholesale acquisition cost; 2023. Available from: http:\/\/truvenhealth.com\/products\/micromedex\/product-suites\/clinical-knowledge\/red-book. [accessed 2023 April]."},{"key":"e_1_3_9_45_1","unstructured":"Centers for Medicare & Medicaid Services. Physician fee schedule; 2023. Available from: https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/PhysicianFeeSched\/. [accessed 2023 April 1]."},{"key":"e_1_3_9_46_1","unstructured":"Centers for Medicare & Medicaid Services. Clinical laboratory schedule; 2023. Available from: https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/ClinicalLabFeeSched\/. [accessed 2023 April]."},{"key":"e_1_3_9_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.4530"},{"key":"e_1_3_9_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01616-3"},{"key":"e_1_3_9_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.07.016"},{"key":"e_1_3_9_50_1","unstructured":"Agency for Healthcare Research and Quality. HCUPnet. Healthcare Cost and Utilization Project (HCUP); 2019. Available from: http:\/\/hcupnet.ahrq.gov\/. [accessed 2019 October 1]."},{"key":"e_1_3_9_51_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011501"},{"key":"e_1_3_9_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.03.2226"},{"key":"e_1_3_9_53_1","unstructured":"Institute for Clinical and Economic Review (ICER). Nadofaragene firadenovec and oportuzumab monatox for BCG-unresponsive non-muscle invasive bladder cancer: effectiveness and value; 2025. Available from: https:\/\/icer.org\/news-insights\/press-releases\/icer-issues-correction-to-final-evidence-report-on-new-therapies-for-bladder-cancer\/. [accessed 2025 June 1]."},{"key":"e_1_3_9_54_1","unstructured":"Schuckman AK Clarke H. From BCG shortage to scientific surge: inside the NMIBC treatment renaissance. Urology Times; 2025. Available from: https:\/\/www.urologytimes.com\/view\/from-bcg-shortage-to-scientific-surge-inside-the-nmibc-treatment-renaissance. [accessed 2025 December 13]."},{"key":"e_1_3_9_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2021.03.024"},{"key":"e_1_3_9_56_1","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-150008"},{"key":"e_1_3_9_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.12.005"},{"key":"e_1_3_9_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2020.02.006"},{"key":"e_1_3_9_59_1","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-170126"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2026.2630599","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T12:40:39Z","timestamp":1772714439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2026.2630599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/13696998.2026.2630599"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2026.2630599","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-12-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}